Applied Genetic Technologies Corp. (AGTC) is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. AGTC's most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3). Its preclinical programs build on the Company's industry leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders. In recent years AGTC has entered into strategic partnerships with companies including Otonomy, a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, and Bionic Sight, an innovator in the emerging field of optogenetics and retinal coding.

Company profile
Ticker
AGTC
Exchange
Website
CEO
Susan Washer
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Ginkgo Bioworks • Bio-Techne • Denali Therapeutics ...
SEC CIK
AGTC stock data
News

Recap Of Tuesday's Biotech Catalysts - End of The Day Summary
26 Jul 22
AGTC Receives Positive Type C Meeting Feedback From The FDA For The Company's Design And Operating Procedures Of Its Planned cGMP Manufacturing Facility
26 Jul 22
Stocks That Hit 52-Week Lows On Friday
15 Jul 22
Twitter Shares Surge Around 8%, Here's 66 Biggest Movers From Yesterday
14 Jul 22
12 Health Care Stocks Moving In Wednesday's Intraday Session
13 Jul 22
Press releases
AGTC to Participate in Upcoming Investor Conferences
1 Aug 22
AGTC Announces Pricing of $10 Million Underwritten Public Offering
12 Jul 22
AGTC Announces Proposed Underwritten Public Offering
12 Jul 22
AGTC to Present at Upcoming American Society of Retina Specialists Annual Meeting
7 Jul 22
Aurion Biotech Appoints Dr. Michael Goldstein as President and Chief Medical Officer
9 Jun 22
Analyst ratings and price targets
Investment data
Securities sold
Number of investors
Calendar
15 May 22
12 Aug 22
30 Jun 23
Financial summary
Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 21 | Jun 20 | Jun 19 | Jun 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 67.85M | 67.85M | 67.85M | 67.85M | 67.85M | 67.85M |
Cash burn (monthly) | 1.64M | 1.81M | 4.53M | 5.19M | 4.67M | 5.08M |
Cash used (since last report) | 7.25M | 7.99M | 20.01M | 22.93M | 20.62M | 22.44M |
Cash remaining | 60.6M | 59.86M | 47.84M | 44.92M | 47.23M | 45.41M |
Runway (months of cash) | 36.9 | 33.1 | 10.6 | 8.7 | 10.1 | 8.9 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Jul 22 | Stephen W Potter | Common Stock | Sell | Dispose S | No | No | 0.7745 | 8,070 | 6.25K | 55,883 |
27 May 22 | Gerald Anthony Reynolds | Common Stock | Sell | Dispose S | No | No | 0.8452 | 3,994 | 3.38K | 21,006 |
18 Feb 22 | Susan B. Washer | Common Stock | Sell | Dispose S | No | No | 2.18 | 9,950 | 21.69K | 143,021 |
18 Feb 22 | Susan B. Washer | Common Stock | Option exercise | Acquire M | No | No | 0.35 | 120,686 | 42.24K | 152,971 |
18 Feb 22 | Susan B. Washer | Stock Option Common Stock | Option exercise | Dispose M | No | No | 0.35 | 120,686 | 42.24K | 0 |
13 Dec 21 | Hope DOyley-Gay | Stock Option Common Stock | Grant | Acquire A | No | No | 2.02 | 180,000 | 363.6K | 180,000 |
Institutional ownership, Q1 2022
36.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 59 |
Opened positions | 10 |
Closed positions | 11 |
Increased positions | 15 |
Reduced positions | 15 |
13F shares | Current |
---|---|
Total value | 27.29M |
Total shares | 18.46M |
Total puts | 49.5K |
Total calls | 50.4K |
Total put/call ratio | 1.0 |
Largest owners | Shares | Value |
---|---|---|
Cantor Fitzgerald, L. P. | 2.36M | $2.52M |
Vanguard | 1.98M | $2.12M |
Millennium Management | 1.65M | $1.76M |
Portolan Capital Management | 1.61M | $1.72M |
Interwest Partners Viii | 1.4M | $2.67M |
Interwest Venture Management | 1.4M | $1.5M |
Intersouth Partners Vi | 1.21M | $4.97M |
BLK Blackrock | 1.12M | $1.2M |
Sabby Management | 970.06K | $1.04M |
Integrated Core Strategies | 717.36K | $2.93M |
Financial report summary
?Competition
Biogen • Ocugen • IVERIC bio • Adverum Biotechnologies • Benitec Biopharma • Allergan • uniQure • Regenxbio • Spark Therapeutics • Voyager TherapeuticsManagement Discussion
- During the years ended June 30, 2021 and 2020, we recognized total revenue of $0.5 million and $2.5 million, respectively.
- Effective April 13, 2021, we entered into a license agreement with a third party whereby we provided nonexclusive rights to our proprietary cone-specific promoter technology for use in the development of two non-competing products. In connection with this agreement, we recognized $0.5 million of license fee revenue during the year ended June 30, 2021.
- During December 2019, Bionic Sight met a milestone related to clearance of filing of an Investigational New Drug application under its collaboration agreement with us and, as a result, we recognized $2.2 million of non-cash collaboration revenue during the year ended June 30, 2020 in connection with in-kind contributions made since inception of the Bionic Sight collaboration agreement. During the year ended June 30, 2020, we also recorded $0.2 million and $0.1 million of grant revenue and other milestone revenue, respectively.
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
afforded, agreed, aninitial, appeal, approach, architectural, ARVO, assay, bid, broader, budget, canhave, chart, clear, coefficient, combat, comply, consecutive, cure, dB, deemed, delisted, delisting, Demographic, diminished, drove, earlier, equivalent, escrow, fact, fewer, fora, fortify, inflation, intent, intraocular, invoice, invoiced, Journal, larger, listing, loglux, meaningful, Nasdaq, paid, panel, perimeter, pressure, prime, proposed, rapidly, regain, reiterated, repeatability, Snellen, Street, substantive, surgical, theofficer, toanofficer, unevaluable, Wall
Removed:
advancement, biologic, committee, criterion, decibel, demonstrate, discretion, enable, launch, November, profile, senior, strategy, twenty
Financial reports
Current reports
8-K
Departure of Directors or Certain Officers
12 Aug 22
8-K
AGTC Announces Proposed Underwritten Public Offering
14 Jul 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
10 Jun 22
8-K
AGTC Announces Positive Three-Month Interim Results from Skyline Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa
16 May 22
8-K
Entry into a Material Definitive Agreement
9 May 22
8-K
AGTC Announces Proposed Public Offering of Common Stock
23 Mar 22
8-K
Departure of Directors or Certain Officers
2 Mar 22
8-K
Results of Operations and Financial Condition
14 Feb 22
8-K
Regulation FD Disclosure
8 Feb 22
8-K
Company on track to report three-month interim study results, including visual acuity, visual sensitivity, mobility and safety data, in Q2 2022
11 Jan 22
Registration and prospectus
424B5
Prospectus supplement for primary offering
14 Jul 22
424B5
Prospectus supplement for primary offering
12 Jul 22
424B5
Prospectus supplement for primary offering
23 Mar 22
424B5
Prospectus supplement for primary offering
21 Mar 22
S-8
Registration of securities for employees
23 Sep 21
S-3
Shelf registration
2 Apr 21
424B5
Prospectus supplement for primary offering
29 Jan 21
424B5
Prospectus supplement for primary offering
27 Jan 21
S-8
Registration of securities for employees
18 Sep 20
424B4
Prospectus supplement with pricing info
7 Feb 20
Other
EFFECT
Notice of effectiveness
13 Apr 21
CORRESP
Correspondence with SEC
7 Apr 21
UPLOAD
Letter from SEC
6 Apr 21
EFFECT
Notice of effectiveness
7 Feb 20
CORRESP
Correspondence with SEC
4 Feb 20
CORRESP
Correspondence with SEC
4 Feb 20
UPLOAD
Letter from SEC
3 Feb 20
CT ORDER
Confidential treatment order
16 Jan 20
CT ORDER
Confidential treatment order
3 Jul 18
EFFECT
Notice of effectiveness
20 Jun 18
Ownership
4
APPLIED GENETIC TECHNOLOGIES / Stephen W Potter ownership change
1 Jul 22
4
APPLIED GENETIC TECHNOLOGIES / Gerald Anthony Reynolds ownership change
31 May 22
4
APPLIED GENETIC TECHNOLOGIES / Susan B. Washer ownership change
22 Feb 22
SC 13G
APPLIED GENETIC TECHNOLOGIES / Portolan Capital Management ownership change
15 Feb 22
SC 13G/A
APPLIED GENETIC TECHNOLOGIES / INTERWEST PARTNERS VIII ownership change
14 Feb 22
SC 13G/A
APPLIED GENETIC TECHNOLOGIES / Stonepine Capital Management ownership change
11 Feb 22
SC 13G/A
APPLIED GENETIC TECHNOLOGIES / Portolan Capital Management ownership change
11 Feb 22
SC 13G/A
APPLIED GENETIC TECHNOLOGIES / Empery Asset Management ownership change
19 Jan 22
4
APPLIED GENETIC TECHNOLOGIES / Hope DOyley-Gay ownership change
15 Dec 21
3
APPLIED GENETIC TECHNOLOGIES / Hope DOyley-Gay ownership change
15 Dec 21
Patents
Utility
Recombinant Aav Production In Mammalian Cells
4 Nov 21
The present invention includes methods and compositions for the production of high titer recombinant Adeno-Associated Virus (rAAV) in a variety of mammalian cells.
Utility
Codon Optimized Nucleic Acid Encoding a Retinitis Pigmentosa Gtpase Regulator (RPGR)
10 Jun 21
This invention relates generally to a codon optimized nucleic acid encoding a retinitis pigmentosa GTPase regulator (RPGR) protein.
Utility
Promoters, Expression Cassettes, Vectors, Kits, and Methods for the Treatment of Achromatopsia and Other Diseases
27 May 21
The present invention provides isolated promoters, transgene expression cassettes, vectors, kits, and methods for treatment of genetic diseases that affect the cone cells of the retina.
Utility
Adeno-associated Virus (Aav) Systems for Treatment of Progranulin Associated Neurodegenerative Diseases or Disorders
20 May 21
The disclosure provides, in part, optimally-modified progranulin (PGRN) cDNA and associated genetic elements for use in recombinant adeno-associated virus (rAAV)-based gene therapy for neurodegenerative disorders characterized by cognitive disruption, behavioral impairment, and deficient lysosomal storage, including familial frontotemporal dementia (FTD), frontotemporal lobar degeneration (FTLD), neuronal ceroid lipofuscinosis (NCL), or Alzheimer's disease (AD).
Utility
Triple Function Adeno-associated Virus (Aav)vectors for the Treatment of C9ORF72 Associated Diseases
20 May 21
The present disclosure provides isolated promoters, transgene expression cassettes, vectors, kits, and methods for treatment of C9ORF72 associated diseases, including ALS and FTD.
Transcripts
2022 Q2
Earnings call transcript
14 Feb 22
2021 Q4
Earnings call transcript
24 Sep 21
2021 Q4
Earnings call transcript
24 Sep 21
2021 Q3
Earnings call transcript
18 May 21
2021 Q2
Earnings call transcript
11 Feb 21
2020 Q4
Earnings call transcript
9 Sep 20
2020 Q3
Earnings call transcript
13 May 20
2007 Q1
Earnings call transcript
9 Jan 20
2020 Q1
Earnings call transcript
13 Nov 19
2019 Q4
Earnings call transcript
26 Sep 19
Reddit threads
Possible 10x NLTX
4 Aug 22
YOLO Stocks You Love for No Good Reason
4 Aug 22
AGTC Receives Favorable FDA Opinion
3 Aug 22
Daily Plays August 02, 2022
2 Aug 22
$AGTC, went up 9% and it's still undervalued
19 Jul 22
Daily Plays July 14, 2022
14 Jul 22
I love these drops 😍
13 Jul 22
$AGTC, down 53.39% to an all-time low of $0.395
13 Jul 22
What Pennystocks are at all time lows? I am writing an extra sentence so I don’t get removed for low effort post
12 Jul 22
$AGTC suddenly drops after-hours to an all-time low of $0.58
12 Jul 22